Author

Gina R. Petroni

Observed name: Gina R Petroni

Institution: University of Virginia

Observed institutions: Northwestern University, University of Virginia Health System, University of Virginia

ORCID: 0009-0008-0571-2820

Observed ORCID: 0009-0008-0571-2820

OpenAlex ID: A5063338490

Ventilatory Assistance Before Umbilical Cord Clamping in Extremely Preterm Infants

2024 · Karen D. Fairchild, Gina R. Petroni, et al. · JAMA Network Open · 38

Physiologic Transition During Delayed Cord Clamping With Assisted Ventilation in Preterm Infants

2025 · Jennifer L. Fang, Karen D. Fairchild, et al. · JAMA Network Open · 5

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)

2026 · Emily K Ninmer, Gina R Petroni, et al. · Journal for ImmunoTherapy of Cancer · 3

Rates and predictors of intraventricular hemorrhage in the ventfirst trial with comparison to a contemporaneous cohort

2026 · Marya L. Strand, Dorothy I. Bulas, et al. · Journal of Perinatology

Table 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S3 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S6 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Figure S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S2 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Supplementary File 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S10 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Data from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Figure S2 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Figure 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Figure 4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S8 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S5 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table 2 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S9 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table S7 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Table 3 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Figure 5 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Figure 2 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)

2026 · Emily K. Ninmer, Gina R. Petroni, et al.

Works count: 68

Citation count: 46

H-index: 3

I10-index: 1